INSUPRO Trademark

Trademark Overview


On Tuesday, October 17, 2017, a trademark application was filed for INSUPRO with the United States Patent and Trademark Office. The USPTO has given the INSUPRO trademark a serial number of 87648362. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 1, 2018. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The INSUPRO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
insupro

General Information


Serial Number87648362
Word MarkINSUPRO
Filing DateTuesday, October 17, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 1, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 2, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 26, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events


Event DateEvent Description
Monday, October 1, 2018ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, October 1, 2018ABANDONMENT - NO USE STATEMENT FILED
Tuesday, February 27, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 2, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 2, 2018PUBLISHED FOR OPPOSITION
Wednesday, December 13, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, November 26, 2017ASSIGNED TO LIE
Thursday, November 9, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, November 9, 2017EXAMINER'S AMENDMENT ENTERED
Thursday, November 9, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, November 9, 2017EXAMINERS AMENDMENT E-MAILED
Thursday, November 9, 2017EXAMINERS AMENDMENT -WRITTEN
Friday, November 3, 2017ASSIGNED TO EXAMINER
Thursday, October 26, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, October 20, 2017NEW APPLICATION ENTERED IN TRAM